Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2023.1332177 Immunology Correction Corrigendum: The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases Navarro-Compán Victoria 1 † Puig Luis 2 † Vidal Silvia 3 Ramírez Julio 4 Llamas-Velasco Mar 5 Fernández-Carballido Cristina 6 Almodóvar Raquel 7 Pinto José Antonio 8 Galíndez-Aguirregoikoa Eva 9 Zarco Pedro 7 Joven Beatriz 10 Gratacós Jordi 11 Juanola Xavier 12 Blanco Ricardo 13 Arias-Santiago Salvador 14 15 16 Sanz Jesús Sanz 17 Queiro Rubén 18 * ‡ Cañete Juan D. 4 * ‡ 1 Department of Rheumatology, Hospital Universitario La Paz, IdiPaz, Madrid, Spain 2 Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain 3 Immunology-Inflammatory Diseases, Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain 4 Arthritis Unit, Department of Rheumatology, Hospital Clínic and Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spain 5 Department of Dermatology, Hospital Universitario La Princesa, Madrid, Spain 6 Department of Rheumatology, Hospital Universitario San Juan de Alicante, Alicante, Spain 7 Department of Rheumatology, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain 8 Department of Rheumatology, Complejo Hospitalario Universitario de A Coruña, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain 9 Department of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain 10 Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain 11 Department of Rheumatology, Medicine Department Autonomus University of Barcelona (UAB), I3PT, University Hospital Parc Taulí Sabadell, Barcelona, Spain 12 Department of Rheumatology, University Hospital Bellvitge, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, Spain 13 Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain 14 Department of Dermatology, Hospital Universitario Virgen de las Nieves, Granada, Spain 15 Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain 16 Department of Dermatology, Facultad de Medicina, Universidad de Granada, Granada, Spain 17 Department of Rheumatology, Hospital Universitario Puerta del Hierro Majadahonda, Madrid, Spain 18 Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

Edited and Reviewed by: Gerald Nabozny, Boehringer Ingelheim, United States

*Correspondence: Juan D. Cañete, jcanete@clinic.cat; Rubén Queiro, rubenque7@yahoo.es

†These authors have contributed equally to this work and share first authorship

‡These authors have contributed equally to this work and share last authorship

 22 11 2023 2023 14 1332177 02 11 2023 13 11 2023 Copyright © 2023 Navarro-Compán, Puig, Vidal, Ramírez, Llamas-Velasco, Fernández-Carballido, Almodóvar, Pinto, Galíndez-Aguirregoikoa, Zarco, Joven, Gratacós, Juanola, Blanco, Arias-Santiago, Sanz, Queiro and Cañete 2023 Navarro-Compán, Puig, Vidal, Ramírez, Llamas-Velasco, Fernández-Carballido, Almodóvar, Pinto, Galíndez-Aguirregoikoa, Zarco, Joven, Gratacós, Juanola, Blanco, Arias-Santiago, Sanz, Queiro and Cañete

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases By Navarro-Compán V, Puig L, Vidal S, Ramírez J, Llamas-Velasco M, Fernández-Carballido C, Almodóvar R, Pinto JA, Galíndez-Aguirregoikoa E, Zarco P, Joven B, Gratacós J, Juanola X, Blanco R, Arias-Santiago S, Sanz J, Queiro R and Cañete JD (2023) Front. Immunol. 14:1191782. doi: 10.3389/fimmu.2023.1191782 IL-17A IL-17F IL-23 spondyloarthritis Th17 cells MAIT cells γδ T cells psoriasis section-in-acceptance Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

In the published article, there was an error in Table 1 as published. The cell corresponding to ixekizumab in HS must be yellow rather than green, since it is not approved for that indication, nor has phase 3 clinical development been published.

Also, there is no data regarding clinical studies using tildrakizumab for IBD, so the color has been changed to yellow.

The legend has been modified for clarification. The changes include the modification from “Green: Shown efficacy” to “Green: approved or shown efficacy in phase 3 clinical trials”.

The corrected Table 1 and its caption “Available therapies targeting IL-17 and IL-23 in IMIDs” appear below.

Available therapies targeting IL-17 and IL-23 in IMIDs.

Mechanism of action Therapy Approved indications* PsO PsA axSpA HS IBD Uveitis
Anti-IL-17A Ixekizumab Plaque psoriasis, psoriatic arthritis, axial spondylarthritis
Secukinumab Plaque psoriasis, psoriatic arthritis, axial spondylarthritis, juvenile idiopathic arthritis
Anti-IL-17RA Brodalumab Plaque psoriasis
Anti-IL-17A and IL-17F Bimekizumab Plaque psoriasis, psoriatic arthritis, and axialspondylarthritis. Phase 3 clinical development completed for hidradenitis suppurativa, EMA approval pending
Anti-IL12/23 Ustekinumab Plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis
Anti-IL23p19 Guselkumab Plaque psoriasis, psoriatic arthritis. In phase 3 clinical development for Crohn’s disease and ulcerative colitis
Risankizumab Plaque psoriasis, psoriatic arthritis, Crohn’s disease. In phase 3 clinical development for ulcerative colitis
Tildrakizumab Plaque psoriasis. In phase 3 clinical development for psoriatic arthritis

axSpA, axial spondyloarthritis; HS, hidradenitis suppurativa; IBD, inflammatory bowel disease; IL, interleukin; PsA, psoriasis arthritis; PsO, psoriasis.

*The table only includes therapies that have been approved by the European Medicines Agency (EMA) or that have published phase 3 clinical development.

Green: approved or shown efficacy in phase 3 clinical trials. Red: Lack of efficacy. Yellow: Insufficient or unclear evidence.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.